Fig. 1

CD16 158 V but not 158 F or 48 H/L polymorphisms enable activity of CD16-CAR transduced T cells. a Schematic overview of used constructs; anti-EGFR monoclonal antibodies cetuximab (IgG1) and panitumumab (IgG2), CD16-CAR with 48 H and 158 V (referred to as VH), 48 L and 158 F (referred to as FL), 48 L and 158 V (referred to as VL) variations and CD16-del, which is devoid of the intracellular moieties. b In total, 300.000 CD16 VH-CAR-, CD16 VL-CAR-, CD16 FL-CAR-, CD16-del-transduced or untransduced T cells were co-cultured for 48 h with 30.000 EGFR⁺ Panc-1 pancreatic cancer cells in the presence or absence of 10 µg/ml of the anti-EGFR antibody panitumumab (IgG2) or increasing doses of the anti-EGFR antibody cetuximab (0.1, 1, and 10 µg/ml; IgG1), as indicated in the figure. IFN-γ production was measured by ELISA. All graphs show mean values of at least three technical replicate and each experiment shown is a representative figure of at least three independent experiments. A two-sided unpaired Student´s t test was used to determine the p-values and a p-value < 0.05 was considered statistically significant